Sarepta therapeutics submits efficacy supplement to expand the elevidys label to include duchenne muscular dystrophy patients without restriction to age or ambulatory status

Cambridge, mass.--(business wire)--sarepta submits efficacy supplement to expand elevidys label to include duchenne patients without restriction to age or ambulatory status.
SRPT Ratings Summary
SRPT Quant Ranking